The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).
 
Hiroshi Nokihara
Honoraria - Boehringer Ingelheim; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Nobuyuki Katakami
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Janssen; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Toyoaki Hida
Honoraria - Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Merck KGaA (Inst); Ono Pharmaceutical (Inst)
 
Fumio Imamura
No Relationships to Disclose
 
Hiroshi Sakai
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Shinji Atagi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Makoto Nishio
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Elekta; Lilly; Nicholas Piramal; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Christoph Helwig
Employment - Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA (Inst)
 
Hiroyuki Achiwa
Employment - Merck Serono
 
Tomohide Tamura
Honoraria - Astellas Pharma; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical